# Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

> **NCT04908865** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 67 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT04908865
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2024-05-23
- **Final completion:** 2024-08-13
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908865, "Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04908865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*